A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid Tumors
A Phase I Clinical Study Evaluating the Safety ,Tolerability, Pharmacokinetics of JS012 in Patients With Advanced or Metastatic Solid Tumors
Sponsor: Shanghai Junshi Bioscience Co., Ltd.
Terminated
Due to the adjustment and change of the sponsor's R\&D strategy, we now plan to voluntarily terminate this clinical trial.
Other terminated trials from Shanghai Junshi Bioscience Co., Ltd.
- Advanced Pancreatic Cancer · Phase PHASE1 · Jan 2025
- Liver Cancer, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Cervical Cancer, MSI-H Colorectal Cancer · Phase PHASE1 · Jan 2024
- Advanced Cancer · Phase PHASE1 · Nov 2023
- Hepatocellular Carcinoma · Phase PHASE1/PHASE2 · Aug 2023
- Advanced Solid Tumors · Phase PHASE1 · Jun 2023
More terminations from Shanghai Junshi Bioscience Co., Ltd.
Other Advanced or Metastatic Solid Tumors trials with similar outcome
This PHASE1 trial investigates Advanced or Metastatic Solid Tumors and is currently terminated or withdrawn. Shanghai Junshi Bioscience Co., Ltd. leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Apr 2023 — Jul 2024 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Jun 2022 — Apr 2023 [monthly]
Recruiting PHASE1
First recorded
Apr 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai Junshi Bioscience Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .